공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

진핵생물 번역 개시 인자 4E(eIF-4E) : 파이프라인 리뷰

Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Pipeline Review, H2 2016

리서치사 Global Markets Direct
발행일 2016년 09월 상품 코드 361641
페이지 정보 영문 38 Pages
가격
US $ 3,500 ₩ 3,979,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 7,958,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 11,937,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


진핵생물 번역 개시 인자 4E(eIF-4E) : 파이프라인 리뷰 Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Pipeline Review, H2 2016
발행일 : 2016년 09월 페이지 정보 : 영문 38 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 각국에서의 진핵생물 번역 개시 인자 4E(이하 eIF-4E)용 치료제 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험의 각 단계별 제품 리스트, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

목차

서론

  • 분석 범위

진핵생물 번역 개시 인자 4E(eIF-4E) 개요

치료제 개발

  • eIF-4 E 치료제의 파이프라인 제품 : 개요

eIF-4E : 각 기업에서 개발중인 치료제

  • 임상시험 단계별
  • 치료 영역별
  • 증상별

파이프라인 제품 개요

  • 후기 단계 제품
  • 초기 단계 제품

각 기업에서 개발중인 치료제

각 대학·연구기관에서 개발중인 치료제

치료제 평가

  • 단일요법 치료제/병용 치료제의 경우
  • 작용기서별
  • 투여 방법별
  • 분자 종류별

치료제 개발에 참여하고 있는 기업

  • eFFECTOR Therapeutics, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Onconova Therapeutics, Inc.

약제 개요

  • 4EGI-1
    • 제품 개요
    • 작용기서
    • 연구개발(R&D)의 진전 상황
  • briciclib sodium
  • ISIS-EIF4ERx
  • SBI-756
  • 종양용 eIF4E 저해용 소분자
  • 자폐증·종양용 eIF4E 저해용 소분자

개발이 휴지 상태인 제품

개발이 중지된 제품

주목할 만한 최신 동향·프레스 릴리스(총 6건)

부록

도표

KSA 16.08.01

Summary

Global Markets Direct's, 'Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Pipeline Review, H2 2016', provides in depth analysis on Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) targeted pipeline therapeutics.

The report provides comprehensive information on the Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E)
  • The report reviews Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) Overview
  • Therapeutics Development
    • Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Products under Development by Stage of Development
    • Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Products under Development by Therapy Area
    • Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Products under Development by Indication
  • Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Products under Development by Companies
  • Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Products under Development by Universities/Institutes
  • Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Companies Involved in Therapeutics Development
    • eFFECTOR Therapeutics, Inc.
    • Ionis Pharmaceuticals, Inc.
    • Onconova Therapeutics, Inc.
  • Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Drug Profiles
    • 4EGI-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • briciclib sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ISIS-EIF4ERx - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBI-756 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit eIF4E for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Translation Initiation Factor-4E for Autism and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Dormant Projects
  • Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Discontinued Products
  • Eukaryotic Translation Initiation Factor 4E (eIF 4F 25 kDa Subunit or mRNA Cap Binding Protein or EIF4E) - Featured News & Press Releases
    • Nov 24, 2015: Scientists identify promising new melanoma drug
    • Oct 29, 2015: Onconova Therapeutics to Present New Data on Briciclib at 2015 AACR-NCI-EORTC Meeting
    • Apr 21, 2015: Onconova Therapeutics Highlights Briciclib at the 2015 American Association of Cancer Research (AACR) Annual Meeting
    • Jan 04, 2011: Isis Initiates Phase II Lung Cancer Trial With ISIS-EIF4ERx In Combination With Carboplatin And Paclitaxel
    • Feb 01, 2006: Lilly Initiates Clinical Trials On Second Cancer Drug Discovered In Isis Collaboration
    • Jun 24, 2002: Expansion Of Antisense Agreement Between Isis And Eli Lilly
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by eFFECTOR Therapeutics, Inc., H2 2016
  • Pipeline by Ionis Pharmaceuticals, Inc., H2 2016
  • Pipeline by Onconova Therapeutics, Inc., H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top
전화 문의
F A Q